Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A

NCT01434511 | Terminated Phase 3 Results DMC

• 1 other identifier: OBI-1-302
• Study Type: interventional
• Target: 1
• Locations: 3 countries
• Sites: 3

Brief Summary

This study is to test whether the study drug (OBI-1) is safe and effective for the treatment of serious bleeding episodes in people with congenital hemophilia A.

Conditions

Hemophilia A

Keywords

hemophilia A; haemophilia A; blood coagulation disorders; hemorrhagic disorders; coagulation protein disorder; hematologic diseases; congenital hemophilia A

Outcome Measures

Primary Outcomes (1)

• Proportion of Serious Bleeding Episodes Responsive to OBI-1

  This study was terminated early and only enrolled one participant. Due to concerns that the participant would be at risk of being re-identified, the study results are not posted. The decision to terminate this study was not related to any safety and/or efficacy concern of OBI-1 in the indication described within the OBI-1-302 study (Congenital Hemophilia A).

  24 hours after initiation of treatment

Secondary Outcomes (13)

• Overall Proportion of Serious Bleeding Episodes Successfully Controlled With OBI-1 Therapy, as Assessed by the Investigator.

  Through 90 days ± 7days following final OBI-1 dose

• Proportion of Bleeding Episodes Responsive to OBI-1 Therapy at Designated Assessment Time Points After the Initiation of Therapy, as Assessed by the Investigator

  Through 90 days ± 7days following final OBI-1 dose

• Frequency of Infusions of OBI-1 Required to Successfully Control Qualifying Bleeding Episodes.

  Through 90 days ± 7days following final OBI-1 dose

• Total Dose of OBI-1 Required to Successfully Control Qualifying Bleeding Episodes.

  Through 90 days ± 7days following final OBI-1 dose

• Total Number of Infusions of OBI-1 Required to Successfully Control Qualifying Bleeding Episodes.

  Through 90 days ± 7days following final OBI-1 dose

Study Arms (1)

OBI-1

EXPERIMENTAL

Biological: OBI-1

Interventions

OBI-1 BIOLOGICAL

intravenous infusion, up to every 2-3 hours for the first 24 hours of treatment

OBI-1

Eligibility Criteria

• Age: 6 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Written informed consent/assent from participant and/or participant's parent or legal representative.
• Participants with congenital hemophilia A with human factor VIII inhibitor ≤30 BU assessed within 90 days prior to study entry.
• Has previously or is currently demonstrating suboptimal hemostatic response to bypassing agents for treatment of bleeding episodes; suboptimal response is determined by the investigator , but minimally includes no or minimal evidence of response after at least two doses of bypassing agents, either for the current or a historic bleeding episode.
• Has an anti-OBI-1 titer ≤ 10 BU
• Has any serious or life-threatening bleeding episode; or requires a surgical procedure that could lead to a serious bleeding episode if not well controlled.
• Is willing and able to follow all instructions and attend all study visits.
• Has no other significant hemostatic abnormality and:
• Platelets ≥100,000/mm-cubed
• Prothrombin time \< 15 seconds
• INR \< 1.3
• Participants taking anti-thrombotics (such as clopidogrel, heparin or heparin analogue) may be included provided three half-lives of the agent have elapsed since the last dose of the agent.

You may not qualify if:

• Hemodynamically unstable after blood transfusion, fluid resuscitation and pharmacologic or volume replacement pressor therapy. This hemodynamic instability is characterized by symptomatic hypotension resulting in vital organ dysfunction, such as cardiac ischemia, oliguria (urine volume \<0.5 mL/kg in the previous six hours), central nervous system hypoperfusion manifested by mental status change such as confusion (unless head injury or intracranial hemorrhage is present), pulmonary compromise, and/or acidosis (manifested by pH and lactate levels).
• Bleeding episode assessed likely to resolve on its own if left untreated.
• Use of hemophilia medication: recombinant factor VIIa within 3 hours prior to OBI-1 administration or activated prothrombin complex concentrate (aPCC) treatment within 6 hours prior to OBI-1 administration
• Prior history of bleeding disorder other than congenital hemophilia A
• Known major sensitivity (anaphylactoid reactions) to porcine or hamster products. Examples include therapeutics of porcine origin (e.g. previously marketed porcine factor VIII, Hyate-C®) and recombinant therapeutics prepared from hamster cells (e.g. Humira®, Advate® and Enbrel®).
• Received any other investigational treatment within 30 days of the first OBI-1 treatment.
• Anticipated need for treatment or device during the study that may interfere with the evaluation of the safety or efficacy of OBI-1, or whose safety or efficacy may be affected by OBI-1.
• Is planning to father a child during the study
• Has abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the investigator, might jeopardize the participant's safety or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.
• Inability or unwillingness to comply with the study design, protocol requirements, or the follow-up procedures.

Sponsors & Collaborators

• Baxalta now part of Shire: lead

Study Sites (3)

Indiana Hemophilia and Thrombosis Center

Indianapolis, Indiana, 46260, United States

Location

Charlotte Maxeke Johannesburg Academic Hospital

Johannesburg, Gauteng, 2193, South Africa

Location

Great Ormond Street Hospital

London, England, WC1N 3JH, United Kingdom

Location

MeSH Terms

Conditions

Hemophilia A; Blood Coagulation Disorders; Hemorrhagic Disorders; Coagulation Protein Disorders; Hematologic Diseases

Condition Hierarchy (Ancestors)

Blood Coagulation Disorders, Inherited; Hemic and Lymphatic Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Results Point of Contact

• Title: Study Director
• Organization: Shire

ClinicalTransparency@shire.com

+1 866 842 5335

Study Officials

• Study Director

  Takeda

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 13, 2011
• First Posted: September 15, 2011
• Study Start: October 3, 2011
• Primary Completion: July 29, 2013
• Study Completion: July 29, 2013
• Last Updated: May 14, 2021
• Results First Posted: December 17, 2014

Record last verified: 2021-04

Locations

US (1); ZA (1); GB (1)